Response duration was adversely affected when pyridoxine was used in combination with altretamine and cisplatin in advanced ovarian cancer patients.
Source: NLP:cisplatin
Cisplatin Interactions
Brand names: Cisplatin
Platinum-based Drug
Route: Intravenous
FDA Black Box Warning
WARNING: NEPHROTOXICITY, PERIPHERAL NEUROPATHY, NAUSEA AND VOMITING and MYELOSUPPRESSION. Nephrotoxicity: cisplatin injection can cause severe renal toxicity, including acute renal failure. Severe renal toxicities are dose-related and cumulative. Ensure adequate hydration and monitor renal function and electrolytes. Consider dose reductions or alternative treatments in patients with renal impairment [see Dosage and Administration ( 2.1 ) and Warnings and Precautions ( 5.1 )]. Peripheral Neuropathy: cisplatin injection can cause dose-related peripheral neuropathy that becomes more severe with repeated courses of the drug [see Warnings and Precautions ( 5.2 )]. Nausea and Vomiting: cisplatin injection can cause severe nausea and vomiting. Use highly effective antiemetic premedication [see Dosage and Administration ( 2.1 ) and Warnings and Precautions ( 5.3 )]. Myelosuppression: cisplatin injection can cause severe myelosuppression with fatalities due to infections. Monitor blood counts accordingly. Interruption of therapy may be required [see Warnings and Precautions ( 5.4 )]. WARNING: NEPHROTOXICITY, PERIPHERAL NEUROPATHY, NAUSEA AND VOMITING, and MYELOSUPPRESSION See full prescribing information for complete boxed warning. Nephrotoxicity: cisplatin injection can cause severe renal toxicity, including acute renal failure. Ensure adequate hydration. Consider dose reductions or alternative treatments in patients with renal impairment. ( 2.1 , 5.1 ) Peripheral Neuropathy: cisplatin injection can cause dose-related peripheral neuropathy. ( 5.2 ) Nausea and Vomiting: cisplatin injection can cause severe nausea and vomiting. Premedicate with antiemetics. ( 2.1 , 5.3 ) Myelosuppression: cisplatin injection can cause severe myelosuppression with fatalities due to infections. Monitor blood counts and interrupt therapy accordingly. ( 5.4 )
Contraindications
4 CONTRAINDICATIONS Cisplatin injection is contraindicated in patients with severe hypersensitivity to cisplatin [see Warnings and Precautions ( 5.4 )] . Severe hypersensitivity to cisplatin ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary Based on human data from published literature, cisplatin injection can cause fetal harm when administered to pregnant women. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Data demonstrates transplacental transfer of cisplatin. Exposure of pregnant women to cisplatin-containing chemotherapy has been associated with oligohydramnios, intrauterine growth restriction, and preterm birth. Cases of neonatal acute respiratory distress syndrome, cytopenias, and hearing loss have been reported. Cisplatin injection administration to animals during and after organogenesis resulted in teratogenicity. A published study in mice showed placental transfer of cisplatin increased with placenta maturation. The background risk of major birth defects and miscarriage for the indicated populations are unknown. However, the background risk in the U.S. general population of major birth defects is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies.
21 interactions on record
Concomitant use of ototoxic drugs with cisplatin increases risk of hearing loss and ototoxicity.
Source: NLP:cisplatin
Risk of ototoxic and nephrotoxic effects when cisplatin and furosemide are given concomitantly.
Source: NLP:furosemide
Risk of ototoxic and nephrotoxic effects if cisplatin and furosemide are given concomitantly. Administer furosemide at lower doses with positive fluid balance and monitor renal function.
Source: NLP:furosemide injection 80 mg/ 10 ml
Concurrent and/or sequential use should be avoided due to potential neurotoxicity and nephrotoxicity.
Source: NLP:gentamicin sulfate
Cisplatin may affect melphalan kinetics by inducing renal dysfunction and altering melphalan clearance.
Source: NLP:melphalan hydrochloride
Caution must be exercised if high-dose methotrexate is administered in combination with cisplatin due to potential nephrotoxicity of both agents.
Source: NLP:methotrexate
Myelosuppression more profound when paclitaxel given after cisplatin; paclitaxel clearance decreased approximately 33% when administered following cisplatin.
Source: NLP:paclitaxel
Concomitant or sequential use may have additive nephrotoxic effects; should be closely monitored and avoided if possible.
Source: NLP:pentamidine isethionate
Response duration was adversely affected when pyridoxine was used in combination with altretamine and cisplatin in advanced ovarian cancer patients.
Source: NLP:cisplatin
Renal toxicity reported when rituximab used in combination with cisplatin.
Source: NLP:rituximab
Renal toxicity reported when rituximab used in combination with cisplatin.
Source: NLP:rituximab-arrx
Combination causes severe myelosuppression with sequence-dependent interaction. At 1.25 mg/m² topotecan with 50 mg/m² cisplatin, severe neutropenia and neutropenic sepsis were reported. Dose reduction required.
Source: NLP:topotecan
Potentially nephrotoxic and neurotoxic drug requiring renal function monitoring when used concurrently with vancomycin.
Source: NLP:vancomycin hydrochloride
Cisplatin + Acidifying AgentsModerate
Plasma levels of anticonvulsant agents may become subtherapeutic during cisplatin therapy, potentially reducing anticonvulsant efficacy.
Source: NLP:cisplatin
Cisplatin + CarbamazepineModerate
CYP3A4 inducer that decreases carbamazepine plasma levels. Carbamazepine levels and/or dosage adjustment may be necessary.
Source: NLP:carbamazepine
Cisplatin + Fosphenytoin SodiumModerate
May decrease phenytoin serum levels; dose adjustment may be required.
Source: NLP:fosphenytoin sodium
MultiHance may compete for MOAT transporter and prolong systemic exposure of cisplatin.
Source: NLP:gadobenate dimeglumine
Cisplatin + PhenytoinModerate
May decrease phenytoin serum levels; monitoring of phenytoin levels recommended.
Source: NLP:phenytoin
Cisplatin + Phenytoin SodiumModerate
May decrease phenytoin serum levels; monitoring of phenytoin levels recommended.
Source: NLP:extended phenytoin sodium
Cisplatin does not affect the pharmacokinetics of ondansetron.
Source: NLP:ondansetron